MesobanK

• Research type

  Research Tissue Bank

• IRAS ID

  245541

• Research summary

  MesobanK

• REC name

  East of England - Cambridge Central Research Ethics Committee

• REC reference

  18/EE/0161

• Date of REC Opinion

  9 Aug 2018

• REC opinion

  Further Information Favourable Opinion

• Data collection arrangements

  MesobanK will collect, process, store and distribute tissue, blood and pleural fluid samples with associated clinical data from patients who have come into contact with asbestos and who have either been diagnosed with mesothelioma or who are being investigated for possible mesothelioma . Research samples will be collected during standard diagnostic/treatment procedures and stored long term. Clinical data will be
  extracted from medical records as well as other sources such as Public Health England (National Cancer Registration and Analysis Service) and held on a bespoke and secure database accessible by staff via a secure password protected web
  interface. Data sent externally will be fully anonymised.
  Patients will be identified and approached by clinical NHS staff and consent will be recorded in writing.
  We hope to collect 100 sample sets per year from tissue collection sites across the UK (Papworth, Leicester, Manchester, Sheffield, Birmingham, Southampton, Glasgow and St Bartholomew’s Hospital, London). Sites have been selected based on the
  number of patients diagnosed in previous years and the presence of a HTA storage license. Samples will be batched at each collection centre before being transferred to Fisher Bioservices for longer term storage. Based on past experience and reviewing literature, we would anticipate that samples will be stable for at least 10 years; however we anticipate withdrawal for use by researchers well inside this time frame.

• Research programme

  Samples will be available to researchers in both publicly or charitably funded institutions as well as those in commercial organisations in the UK, EEA, Australia, New Zealand, USA and Canada. Applications from organisations in other countries will be considered as long as Mesobank is satisfied that appropriate governance and regulatory standards are in place and will be adhered to. A Research Advisory Board will consider applications to the MesobanK bioresource for use of stored tissue and data. Samples will only be supplied on a ‘defined-use’ basis. Conditions of access to samples will include: 1) Research linked to improving prevention, diagnosis and treatment of asbestos related disease 2) Acknowledgement of MesobanK in publications 3) Requirement to share the data obtained Discussions with active researchers working in the field of Mesothelioma found that the following areas of research are likely to be of interest over the next few years: i) Genome wide approaches to identify frequently mutated cancer genes in mesothelioma. ii)Sequencing of mesothelioma genome iii)Identification of cancer signalling pathways that can be targeted with known or novel compounds. iv)Novel drug development for asbestos related disease including mesothelioma.

• Storage license

  11074

• RTBTitle

  MesobanK

• Establishment organisation

  Royal Papworth Hospital NHS Foundation Trust

• Establishment organisation address

  Royal Papworth Hospital

  Papworth Everard, Cambridge

  CB23 3RE